{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-067375","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2022-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.038619+00:00","generated_at":"2026-06-25T05:17:26.638311+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Regeneron enters amended deal with Sanofi for full rights to Libtayo; pays $900M upfront","bullets":["Regeneron gains sole worldwide rights to develop and commercialize Libtayo, effective upon regulatory approvals.","Regeneron will pay Sanofi $900M upfront within 10 business days of effective date.","Regeneron will pay an 11% royalty on Libtayo net sales through March 2034, plus up to $200M in milestone payments.","Development cost reimbursement rate under Antibody LCA increased from 10% to 20% effective April 1, 2022.","Transition services, distribution, and manufacturing agreements support the handover from Sanofi."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-067375","json":"https://secwatch.observer/filing/0001104659-22-067375.json","markdown":"https://secwatch.observer/filing/0001104659-22-067375.md","text":"https://secwatch.observer/filing/0001104659-22-067375.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465922067375/0001104659-22-067375-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465922067375/tm2217255d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T05:17:26.638311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}